---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-086271"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:05:38.614277+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rigel Q2 revenue $36.8M, net loss narrows to $1.0M; GAVRETO launch adds $1.9M

## Summary
- Total Q2 revenue $36.8M; TAVALISSE $26.4M (+24% YoY), REZLIDHIA $5.2M (+102% YoY), GAVRETO $1.9M (launched June 27).
- Net loss narrowed to $1.0M ($0.06/share) from $6.6M loss in Q2 2023; approaching net income break-even.
- Completed NDA transfer of GAVRETO; product commercially available from Rigel beginning June 27.
- Phase 1b trial of R289 in LR-MDS enrolling fourth dose level; preliminary data expected by end of 2024.
- Cash and investments $49.1M as of June 30, essentially flat from March 31.

## SEC filing metadata
- accession: 0001104659-24-086271
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000110465924086271/0001104659-24-086271-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000110465924086271/tm2420634d4_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-086271
- JSON: https://secwatch.observer/filing/0001104659-24-086271.json
- Plain text: https://secwatch.observer/filing/0001104659-24-086271.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.